|Bid||0.0000 x 800|
|Ask||4.0800 x 1200|
|Day's Range||1.5650 - 1.6400|
|52 Week Range||1.0500 - 2.6300|
|Beta (5Y Monthly)||1.85|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 15, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.50|
In 2007 Michael Tardugno was appointed CEO of Celsion Corporation (NASDAQ:CLSN). This report will, first, examine the...
Independent Data Monitoring Committee (iDMC) Unanimously Recommends Continuation of Phase III OPTIMA Study at First Pre-Planned Efficacy AnalysisIndependent Data Safety.
Celsion Corporation (CLSN), an oncology drug development company, today announced that results from an independent study of a lyso-thermosensitive liposomal doxorubicin (LTLD) was published in the peer-reviewed publication, International Journal of Hyperthermia showing that real-time fluorescence imaging can visualize uptake of LTLD during delivery, and can predict tumor drug uptake in response to heat. ThermoDox® is Celsion’s heat-activated liposomal formulation of doxorubicin currently in Phase III development for the treatment of primary liver cancer, also known as hepatocellular carcinoma (HCC).
Long term investing works well, but it doesn't always work for each individual stock. We really hate to see fellow...
Celsion Corporation (CLSN) announced today that the Company will host a conference call to discuss financial results for the quarter ended September 30, 2019 and provide an update on its development programs for ThermoDox®, its proprietary heat-activated liposomal encapsulation of doxorubicin and GEN-1, an IL-12 DNA plasmid vector formulated into a nanoparticle with a non-viral delivery system at 11:00 a.m. EST on Friday, November 15, 2019. On November 4, 2019 the Company announced that the independent Data Monitoring Committee (iDMC) unanimously recommended the OPTIMA Study continue according to protocol. The recommendation was based on a review of blinded safety and data integrity from 556 patients enrolled in the Company’s multinational, double-blind, placebo-controlled pivotal Phase III study with ThermoDox® plus RFA in patients with HCC.
Celsion Corporation (CLSN) today announced that the independent Data Safety Monitoring Board (DSMB) has completed its safety review of data from the first eight patients enrolled in the ongoing Phase I/II OVATION 2 Study. Based on the DSMB's recommendation, the study will continue as planned and the Company will proceed with completing enrollment in the Phase I portion of the trial. The OVATION 2 Study combines GEN-1, the Company's IL-12 gene-mediated immunotherapy, with the standard of care for the treatment of newly diagnosed patients with Stage III and IV ovarian cancer who will undergo standard neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS).
The Data Monitoring Committee Signals that Patient Safety Data and Data Quality Meets Expectations and Company is to Proceed to Next Interim Analysis. The Pooled HEAT Study Data Demonstrated a Median PFS of 16.8 months While the Latest Pooled OPTIMA Study Data Demonstrates Medium PFS of 17.3 months. LAWRENCEVILLE, N.J. , Nov. 04, 2019 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that the independent Data Monitoring Committee (iDMC) has unanimously recommended the OPTIMA Study continue according to protocol.
Celsion Corporation (CLSN), an oncology drug development company, today announced it has received approval from the New Jersey Economic Development Authority’s (NJEDA) Technology Business Tax Certificate Transfer (NOL) program to sell the Company’s unused New Jersey net operating losses (NOLs) and R&D tax credits. The exact percentage of NOL’s to be sold will be determined by the NJEDA after reviewing all qualified applications. In 2018, the Company received approval from the NJEDA to sell $11.1 million of its unused New Jersey net operating losses for the tax years 2011 through 2017 and was able to transfer this credit and receive approximately $10.5 million of net cash proceeds in the fourth quarter of 2018.
Celsion Corporation (CLSN), an oncology drug-development company, announces that Michael Tardugno, Chairman, President and Chief Executive Officer and Khursheed Anwer, Executive Vice President and Chief Scientific Officer will present at the Chardan 3rd Annual Genetic Medicines Conference on Monday, October 7, 2019 at 9:00 a.m. Eastern time. Management’s participation will take the form of a “Fireside Chat” and will primarily focus on the Company’s development program for GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer.
Celsion Corporation (CLSN), an oncology drug-development company, announces it co-sponsored a symposium focused on hepatocellular carcinoma (HCC) at the recent 13th Annual Conference of the International Liver Cancer Association (ILCA). Other sponsors included Bayer Healthcare Pharmaceuticals, Inc. and Exelixis, Inc., both of whom provide therapeutics for the treatment of advanced HCC. The symposium’s timing verges on the upcoming meeting of the Data Monitoring Committee’s review of the first interim data for the Company’s Phase III OPTIMA Study of its lead drug candidate, ThermoDox®, to treat HCC.
Celsion Corporation's (NASDAQ:CLSN): Celsion Corporation, a development stage oncology drug company, focuses on the...
Celsion Corporation (CLSN), an oncology drug-development company, announces that a study from a single site in China titled “Thermosensitive liposomal doxorubicin plus radiofrequency ablation increased tumor destruction and improved survival in patients with medium and large hepatocellular carcinoma: A randomized, double-blinded, dummy-controlled clinical trial in a single center” has been published in the Journal of Cancer Research and Therapeutics. The data from this single site at the Peking University Cancer Hospital and Institute in Beijing show an overall survival (OS) improvement of 22.5 months in patients with 3-7 cm unresectable hepatocellular carcinoma (HCC) tumors receiving combined radiofrequency ablation (RFA) and ThermoDox®, compared with the use of RFA alone.
First Pre-Planned Efficacy Analysis of the Phase III OPTIMA Study Planned for Mid-October Strong Balance Sheet Plus the Non-Dilutive Sale of $4 Million of New.
NIH’s Independent Analysis of Celsion’s Phase III HEAT Study Confirms Increasing Radiofrequency Ablation (RFA) Heating Time + ThermoDox® Improves Overall Survival with.
Celsion Corporation (CLSN), an oncology drug-development company, announces that Premal H. Thaker, M.D., MSc., Professor of Obstetrics and Gynecology-Division of Gynecologic Oncology at Washington University School of Medicine in St. Louis, led an expert call on the ovarian cancer treatment landscape and emerging opportunities hosted by Oppenheimer & Co. Inc. on August 8th. Dr. Thaker is active in the development of GEN-1, Celsion’s DNA-based, IL-12 immunotherapy for the treatment of ovarian cancer.
LAWRENCEVILLE, N.J., Aug. 08, 2019 -- Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss financial results for the.
Celsion (CLSN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Celsion Corporation (CLSN), an oncology drug-development company, announces the prescribed number of events has been reached for the first prespecified interim analysis of the OPTIMA Phase III Study with ThermoDox® plus RFA (radiofrequency ablation) in patients with hepatocellular carcinoma (HCC), or primary liver cancer. Following preparation of the data, the first interim analysis will be conducted by the Independent Data Monitoring Committee (iDMC). The Company expects the iDMC meeting to occur by mid-October.
If you own shares in Celsion Corporation (NASDAQ:CLSN) then it's worth thinking about how it contributes to the...
Celsion Corporation (CLSN), an oncology drug-development company, announces that the University Medical Center Utrecht in the Netherlands has received Institutional Review Board (IRB) approval to begin a Phase I study to determine the safety, tolerability and feasibility of ThermoDox® (lyso-thermosensitive liposomal doxorubicin) in combination with Magnetic Resonance Guided High Intensity Focused Ultrasound (MR-HIFU) hyperthermia and cyclophosphamide therapy for the local treatment of the primary tumor in metastatic breast cancer (mBC).
NEW YORK, NY / ACCESSWIRE / May 15, 2019 / Celsion Corp. (NASDAQ: CLSN ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 15, 2019 at 11:00 AM Eastern Time. ...